PHARMACY

Emdeon completes transition from CaparioOne to the Emdeon One brand

BY Michael Johnsen

 
 
NASHVILLE, Tenn. — Emdeon, a provider of healthcare revenue and payment cycle management and clinical information exchange solutions, on Monday announced the completion of the transition from CaparioOne to the Emdeon One brand, and the addition of a new Advanced Denials Management service to be integrated within the Emdeon One portal.
 
Emdeon One is a cloud-based platform that enables healthcare providers to use a real-time solution to check eligibility, submit and track claims, manage rejections and denials and accept patient payments at the point of care, online or over the phone, all from one integrated platform. Emdeon One also provides a thorough reporting suite that helps providers monitor performance and identify trends and issues that impact their bottom line.
 
“We designed the new Advanced Denials Management service based on feedback from our customers who were looking for a way to simplify the often tedious and lengthy denials management process,” said Jim Riley, general manager of revenue cycle technologies for Emdeon. “This new service will enhance the value of Emdeon One to our customers by helping providers keep more of the money they’re owed and ultimately reducing the cost of care overall.”
 
According to industry estimates, the average cost to rework a denied claim is $25, and more than 65% of all denied claims are never appealed. With the new Advanced Denials Management service, available through Emdeon One, providers can simplify the process of searching for and identifying denied claims, and can quickly create and send appeal letters. The new service also offers detailed reports showing important information for identifying, classifying and determining root causes for denials, helping providers pinpoint opportunities for improvement within their billing processes.
 
“As providers are being challenged with new reimbursement models, such as patient-pay and pay-for-performance, it’s more important than ever to have the tools to make getting paid easier,” Riley said. “In addition, ICD-10 is upon us once again and industry experts are strongly recommending that providers have a solid denials management solution in place long before the deadline to combat what will likely be a spike in denials after the October 2015 deadline. Emdeon One with its new Advanced Denials Management service gives providers those tools in a single place with a single solution.”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Rx Response moves to alert status in response to Ebola, provides resources to retail pharmacy

BY Michael Johnsen

WASHINGTON — Rx Response on Friday moved to alert status in response to the concern about Ebola in the United States, the organization announced. 
 
Rx Response has urged members of the pharmacy community to provide a calming and educated voice in the community by reminding patients that that risk of Ebola infection here in the United States is very low. Rx Response also is urging pharmacists to remind people that there are many other endemic diseases and conditions that are far more likely to have similar symptoms to acute Ebola infection, such as influenza. On this front, Rx Response has urged pharmacists to reinforce in this Ebola environment the importance of people protecting themselves for the upcoming flu season by getting a flu shot.
 
In response to the need for information, Rx Response has developed a number of resources for community pharmacists, owners and retail pharmacy staff. Specifically, Rx Response has developed:
 
Rx Response also has responded to a number of public and private sector requests for information, including questions from pharmacists on what to do with a sick patient in the pharmacy.
 
Rx Response is a charitable non-profit with members comprising the bio-pharmaceutical supply chain whose mission is to help ensure the continued flow of medicine during times of emergency.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Bartell Drugs to open new Ballard store

BY Antoinette Alexander

 

SEATTLE — Regional pharmacy retailer Bartell Drugs plans to open a new store in 2016 at Ballard Commons, a mixed-use development planned for the site currently occupied by the Bartell Drugs store at 5605 22nd Ave N.W.

The new store will mark the sixth Bartells location in Ballard since 1911.

The new 14,000-square-foot location will be the major retail anchor at Ballard Commons and will include underground parking for Bartell Drugs customers. 
Earlier this year, Seattle-based Bartell Drugs opened a full-service “next generation” store at 1500 N.W. Market Street, introducing new services, product offerings and customer convenience features.
 


Upon closure of the store at 22nd Ave N.W., in January 2015, Bartell Drugs will continue to serve customers at the recently opened Bartell’s location at 15th and Market. 
 


“This is another milestone in our longtime commitment to Ballard. During construction of the new store, we look forward to serving customers at our Market Street location,” stated George D. Bartell, chairman and CEO. 
 


Ballard Commons, a development by Seattle-based Henbart, is a mixed-use development with two contemporary, companion buildings featuring 80 apartments, four townhomes that front Ballard Commons Park, loft-style office space and retail with Bartell Drugs as the anchor tenant. Ballard Commons is designed to include courtyard areas and landscaped grounds, giving it a “campus-like” feel.
 


Founded in Seattle in 1890, Bartell Drugs operates 63 locations in King, Snohomish and Pierce counties and is the nation's oldest family-owned drug store chain.  
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?